NeuroSense Therapeutics (NRSNW) to Release Earnings on Wednesday

NeuroSense Therapeutics (NASDAQ:NRSNW) is projected to announce its resultson Wednesday, March 25th. Analysts expect NeuroSense Therapeutics to post earnings of ($0.1050) per share for the quarter.

NeuroSense Therapeutics Stock Down 8.7%

NASDAQ:NRSNW opened at $0.19 on Tuesday. NeuroSense Therapeutics has a fifty-two week low of $0.16 and a fifty-two week high of $1.00. The firm’s fifty day simple moving average is $0.24 and its 200-day simple moving average is $0.32.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.